Fri, November 16, 2018
Thu, November 15, 2018
Wed, November 14, 2018
Tue, November 13, 2018
Mon, November 12, 2018
Fri, November 9, 2018
Thu, November 8, 2018
Wed, November 7, 2018
Tue, November 6, 2018
Mon, November 5, 2018
Fri, November 2, 2018
Thu, November 1, 2018

Joel Beatty Maintained (SRPT) at Strong Buy with Increased Target to $188 on, Nov 6th, 2018

  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. ith-increased-target-to-188-on-nov-6th-2018.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Joel Beatty of Citigroup, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $174 to $188 on, Nov 6th, 2018.

Joel has made no other calls on SRPT in the last 4 months.



There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 0 agree with Joel's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Joel


  • Alethia Young of "Credit Suisse" Initiated at Buy and Held Target at $178 on, Thursday, September 6th, 2018
  • Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Wednesday, August 1st, 2018